LUNAR®-OTC (ARCT-810)
Ornithine Transcarbamylase Deficiency
Phase 2Active, Recruiting
Key Facts
Indication
Ornithine Transcarbamylase Deficiency
Phase
Phase 2
Status
Active, Recruiting
Company
About Arcturus Therapeutics
Arcturus Therapeutics is a fully integrated, commercial-stage biotech focused on developing mRNA medicines for infectious diseases and rare genetic disorders. Its key achievement is the global approval of KOSTAIVE®, the world's first authorized self-amplifying mRNA COVID-19 vaccine, validating its proprietary technology platforms. The company's strategy is to leverage its LUNAR® delivery and STARR™ saRNA platforms to build a diversified pipeline, advance wholly-owned rare disease programs, and expand through strategic partnerships for vaccines and therapeutics.
View full company profile